Want to see IN:ORCHPHARMA full AI Analyst Report?

Orchid Pharma Limited (ORCHPHARMA) Price & Analysis

0 Followers

ORCHPHARMA Stock Chart & Stats

₹987.90

-₹2.60(-0.26%)

At close: Jul 28 4:00 PM EDT

₹987.90

-₹2.60(-0.26%)

Day’s Range― - ―

52-Week Range₹471.30 - ₹1,142.65

Previous CloseN/A

Volume44.02K

Average Volume (3M)5.52K

Market Cap

₹54.85B

Enterprise Value₹36.85K

Total Cash (Recent Filing)₹832.11M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)647.5

Beta1.26

Next Earnings

Nov 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield16.67%

Share Statistics

EPS (TTM)1.71

Shares Outstanding50,719,105

10 Day Avg. Volume4,446

30 Day Avg. Volume5,516

Financial Highlights & Ratios

PEG Ratio-1.50

Price to Book (P/B)1.90

Price to Sales (P/S)3.02

P/FCF Ratio-8.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)8

Revenue Forecast (FY)₹12.88B

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetA predominantly equity-funded balance sheet provides financial resilience and reduces dependence on borrowing. Lower leverage can preserve capacity to fund operations, withstand weaker earnings periods, and pursue business investments without excessive interest or refinancing pressure.

Improved Profitability BaseThe shift from losses to sustained profitability indicates that Orchid Pharma has established a stronger earnings base than earlier in the period. Continued net profitability can support reinvestment and balance-sheet strength, even though the latest year showed weaker operating performance.

Multi-year Revenue ExpansionStrong revenue expansion across FY2022–FY2025 demonstrates that the business has previously been able to grow its top line over several years. That history provides evidence of market demand and commercial traction, although renewed growth is needed after the latest annual decline.

Bears Say

Recent Revenue ContractionThe FY2026 revenue decline interrupts the company’s earlier expansion and raises concern about the durability of demand and commercial momentum. If the contraction persists, it could reduce operating leverage, limit reinvestment capacity, and make recovery in earnings more difficult.

Sharp Operating-profit DeteriorationA sharp EBIT decline signals weaker underlying operating economics than the headline net-profit result suggests. Sustained margin pressure would reduce earnings quality and leave less internal funding for growth, while any one-off contribution would make recent profitability less dependable.

Inconsistent Cash GenerationRecurring negative free cash flow weakens financial flexibility because accounting profits and operating cash are not consistently translating into funds available after investment. The large FY2026 outflow may constrain self-funded growth and increase reliance on financing or cash reserves.

Orchid Pharma Limited News

Orchid Pharma Calls AGM to Ratify Post-Merger Financials and Key Governance Moves

An update from Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) is now available. Orchid Pharma Limited has released its...

16d ago

Orchid Pharma Files FY 2025-26 Business Responsibility and Sustainability Report

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) has issued an update. Orchid Pharma Limited, a Dhanuka Group company in...

16d ago

Orchid Pharma Board Sets Cost Auditor, Elevates Director and Finalizes AGM Framework

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) has shared an announcement. Orchid Pharma Limited’s board met on September 3,...

20d ago

Orchid Pharma Completes Dhanuka Laboratories Merger, Ups Authorised Capital

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) has issued an announcement. Orchid Pharma Limited has implemented a merger scheme...

2M ago

Orchid Pharma Finalizes Merger with Dhanuka, Boosts Authorised Capital and Sets Record Date

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) just unveiled an announcement. Orchid Pharma Limited has announced that the merger...

2M ago

Orchid Pharma says NCLT dismisses DBS Bank lease rent claim with no impact on operations

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) has shared an announcement. Orchid Pharma has disclosed that the National Company...

5M ago

ORCHPHARMA FAQ

What was Orchid Pharma Limited’s price range in the past 12 months?

Orchid Pharma Limited lowest stock price was ₹471.30 and its highest was ₹1142.65 in the past 12 months.

What is Orchid Pharma Limited’s market cap?

Orchid Pharma Limited’s market cap is ₹54.85B.

When is Orchid Pharma Limited’s upcoming earnings report date?

Orchid Pharma Limited’s upcoming earnings report date is Nov 16, 2026 which is in 54 days.

How were Orchid Pharma Limited’s earnings last quarter?

Orchid Pharma Limited released its earnings results on Aug 14, 2026. The company reported ₹0.636 earnings per share for the quarter, missing the consensus estimate of ₹3.6 by -₹2.964.

Is Orchid Pharma Limited overvalued?

According to Wall Street analysts Orchid Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Orchid Pharma Limited pay dividends?

Orchid Pharma Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of 16.67%. See more information on Orchid Pharma Limited dividends here

What is Orchid Pharma Limited’s EPS estimate?

Orchid Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Orchid Pharma Limited have?

Orchid Pharma Limited has 50,719,105 shares outstanding.

What happened to Orchid Pharma Limited’s price movement after its last earnings report?

Orchid Pharma Limited reported an EPS of ₹0.636 in its last earnings report, missing expectations of ₹3.6. Following the earnings report the stock price went up 1.316%.

Which hedge fund is a major shareholder of Orchid Pharma Limited?

Currently, no hedge funds are holding shares in IN:ORCHPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Orchid Pharma Limited

Operating primarily within India, Orchid Pharma Limited is a pharmaceutical firm specializing in the creation, production, and commercialization of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), and nutraceutical products. Its comprehensive API portfolio encompasses oral and injectable cephalosporins, various veterinary pharmaceuticals, and non-antibiotic substances. The company maintains a multi-faceted therapeutic footprint, with offerings in areas such as anti-infectives, anti-inflammatory agents, central nervous system disorders, cardiovascular health, and nutraceuticals, alongside other oral and sterile formulations. Furthermore, it provides sophisticated new drug discovery (NDD) and pharmaceutical research and development (R&D) services. Orchid Pharma also engages in global trade, distributing its products to roughly 40 nations worldwide. Additionally, it offers comprehensive liaison and support services to its clientele, covering areas like regulatory compliance, pharmacovigilance, product testing and release, sample retention, coordination with service providers, and business expansion initiatives. The entity, originally incorporated as Orchid Chemicals & Pharmaceuticals Limited, adopted its current name, Orchid Pharma Limited, in October 2015. Established in 1992, its corporate headquarters are situated in Chennai, India. The company operates as a subsidiary of Dhanuka Laboratories Limited.